AbCellera Biologics Inc. ABCL Payments To Acquire (Proceeds from) Long Term Investments And Other Assets
Payments To Acquire (Proceeds from) Long Term Investments And Other Assets at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:PaymentsToAcquireProceedsFromLongTermInvestmentsAndOtherAssets.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s payments to acquire (proceeds from) long term investments and other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s payments to acquire (proceeds from) long term investments and other assets?
- AbCellera Biologics Inc. (ABCL) reported payments to acquire (proceeds from) long term investments and other assets of $105K in Q1 2026.
- How has AbCellera Biologics Inc.'s payments to acquire (proceeds from) long term investments and other assets changed year-over-year?
- AbCellera Biologics Inc.'s payments to acquire (proceeds from) long term investments and other assets decreased by 98.6% year-over-year, from $7.48M to $105K.
- What is the long-term trend for AbCellera Biologics Inc.'s payments to acquire (proceeds from) long term investments and other assets?
- Over 2 years (2022 to 2025), AbCellera Biologics Inc.'s payments to acquire (proceeds from) long term investments and other assets has grown at a -0.8% compound annual growth rate (CAGR), from $17.37M to $17.09M.
- What does payments to acquire (proceeds from) long term investments and other assets mean?
- This represents the net cash flow resulting from the purchase or sale of long-term financial assets, such as strategic investments or other non-current holdings. It reflects the company's capital allocation strategy regarding its surplus cash or long-term financial positioning. Investors track this to understand how the company is deploying capital outside of its core operating activities.